The complaint filed against the medical technology firm alleges that executives misled shareholders regarding the true state of their business operations. According to the litigation, PROCEPT utilized a discount structure that encouraged customers to purchase handpieces far beyond actual procedure demand. This practice reportedly allowed the company to pull forward future sales, creating an illusion of growth while masking a significant surplus of field inventory, estimated at over 10,000 units by the end of the class period.

Legal representatives from Glancy Prongay Wolke & Rotter LLP are currently organizing the claim, asserting that the company’s public statements lacked a reasonable basis and concealed operational risks. Investors who purchased shares during the specified window are not required to take immediate action to remain part of the class, though those wishing to influence the litigation as lead plaintiff must file their motions with the court before the September 22 deadline.